Back to library
Immune & Longevity
Limited human evidence

Thymosin Alpha-1

Thymosin alpha-1 is a naturally occurring thymic peptide with immune-modulating properties, marketed outside the United States under the brand name Zadaxin.

Regulatory status: Approved in a number of countries outside the US (as Zadaxin) for uses including chronic hepatitis B and C and as an immune adjunct, but not FDA-approved. In the US it is available only as a compounded or research peptide.

Default vial

10 mg

Default mix

2 mL

Reported range

1.5–3.2 mg

Draw (U-100)

30 u

Subcutaneous
Twice weekly
8w on / 4w off

Often a loading phase twice weekly, then tapered.

What it is

  • A 28-amino-acid peptide fragment derived from prothymosin alpha, originally isolated from thymic tissue.
  • Made synthetically today rather than extracted, and sold internationally as Zadaxin.
  • Typically given by subcutaneous injection.
  • Has a longer international clinical history than most compounds in this library.

How it is described to act

  1. 1

    Absorbed into systemic circulation after subcutaneous injection.

  2. 2

    Proposed to interact with receptors on immune cells including T-lymphocytes and dendritic cells, per the pharmacology accompanying its international labelling.

  3. 3

    Reported downstream effects include modulation of Toll-like receptor signalling and cytokine production.

  4. 4

    Studied clinically outside the US in chronic viral hepatitis, as a vaccine adjuvant, and in some sepsis and immunocompromised-patient settings.

What the research has looked at

Chronic viral hepatitis

  • Non-US clinical trials and regulatory filings supporting Zadaxin approval reported improved viral response markers in chronic hepatitis B and C patients in some, though not all, trials.

Immune modulation

  • PubMed-indexed publications from 2025–2026 continue to study thymosin alpha-1 in infectious-disease and immune-modulation contexts, showing ongoing research interest without a US regulatory filing.

Strength of evidence: Limited human evidence

There is genuine human trial and marketing history abroad, but no FDA approval and no pivotal-trial evidence accepted by US regulators.

Some human data exist, but they are small, short, or not designed to answer the questions people ask online.

Reported cautions and unknowns

  • International labelling and published trials describe it as generally well tolerated, with injection-site reactions the most common adverse event. No FDA-reviewed US safety dataset exists.
  • Compounded material in the US is not FDA-approved, so purity, dosing and sterility are not verified the way an approved drug's are.

References

  1. 1.Recent thymosin alpha-1 literature, PubMed (2025)
  2. 2.Zadaxin (thymosin alpha-1) product information, SciClone Pharmaceuticals

Handling this vial

  • Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
  • Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
  • Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).

Thymosin Alpha-1 questions people ask

How do you reconstitute Thymosin Alpha-1?

A common starting point for a 10 mg vial of Thymosin Alpha-1 is 2 mL of bacteriostatic water, which gives 5 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.

How many units of Thymosin Alpha-1 is one dose?

At 5 mg per mL, that works out to about 30 units on a U-100 insulin syringe for a 1500 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.

What dosing schedule is reported for Thymosin Alpha-1?

Published and community sources describe 1.5–3.2 mg, subcutaneous, twice weekly, typically run 8 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.

How should Thymosin Alpha-1 be stored?

Lyophilized Thymosin Alpha-1 vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.

Read this before you act on anything above

Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.

More in Immune & Longevity